SEC Form 4 · accession 0001225208-18-004949

BOSTON SCIENTIFIC CORP · BSX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP,Pres Urology,Pelvic Health

Period of report

Feb 28, 2018

Accepted (ET)

Mar 1, 2018 · 4:37 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000885725

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Feb 28, 2018	M	4,398	$0.00	A	33,107	D
Common Stock^F1	Feb 28, 2018	M	2,443	$0.00	A	35,550	D
Common Stock	Feb 28, 2018	F	3,041	$27.26	D	32,509	D
Common Stock^F3	Feb 28, 2018	S	4,508	$27.5445	D	28,001	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Deferred Stock Units^F1,F4	—	Feb 28, 2018	M	4,398	D	—	Feb 28, 2018	Common Stock	4,398	0	D
Deferred Stock Units^F1,F5	—	Feb 28, 2018	M	2,443	D	—	Feb 28, 2022	Common Stock	2,443	9,776	D

F1Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
F3Represents the weighted average sale price. These shares were sold in multiple transactions at $27.52 and $27.575. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
F5Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.